Travere Therapeutics, Inc. (TVTX)
NASDAQ: TVTX · Real-Time Price · USD
40.89
+0.08 (0.20%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Travere Therapeutics Stock Forecast
Stock Price Forecast
The 13 analysts that cover Travere Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $40.62, which forecasts a -0.66% decrease in the stock price over the next year. The lowest target is $25 and the highest is $56.
Price Target: $40.62 (-0.66%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Travere Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 7 | 7 |
| Buy | 6 | 6 | 6 | 6 | 5 | 4 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15 | 15 | 15 | 15 | 14 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Strong Buy Maintains $54 → $56 | Strong Buy | Maintains | $54 → $56 | +36.95% | Apr 24, 2026 |
| Citigroup | Citigroup | Strong Buy Maintains $48 → $53 | Strong Buy | Maintains | $48 → $53 | +29.62% | Apr 14, 2026 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $47 → $56 | Strong Buy | Maintains | $47 → $56 | +36.95% | Apr 14, 2026 |
| Wedbush | Wedbush | Buy Maintains $39 → $44 | Buy | Maintains | $39 → $44 | +7.61% | Apr 14, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $49 → $54 | Strong Buy | Maintains | $49 → $54 | +32.06% | Apr 14, 2026 |
Financial Forecast
Revenue This Year
710.38M
from 490.73M
Increased by 44.76%
Revenue Next Year
962.67M
from 710.38M
Increased by 35.51%
EPS This Year
0.17
from -0.29
EPS Next Year
1.97
from 0.17
Increased by 1,042.01%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 976.9M | 1.3B | ||||||
| Avg | 710.4M | 962.7M | ||||||
| Low | 583.1M | 715.4M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 99.1% | 76.7% | ||||||
| Avg | 44.8% | 35.5% | ||||||
| Low | 18.8% | 0.7% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 1.48 | 6.26 | ||||||
| Avg | 0.17 | 1.97 | ||||||
| Low | -0.64 | 0.47 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | 3,530.4% | ||||||
| Avg | - | 1,042.0% | ||||||
| Low | - | 172.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.